Orca Bio’s Post

We’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2 + MBC - Paolo Tarantino #Cancer #DanaFarberCancerInstitute #Govitecan #HER2 #OncoDaily #Oncology

✨ Key takeaways from ASCO 2024 The American Society of Clinical Oncology (ASCO) Annual Meeting is a major conference where oncologists from around the world gather to unveil the latest research and innovations. This meeting uncovered exciting insights on breast cancer that we compiled in our latest blog. Read the key highlights covering groundbreaking predictive testing, drug developments, clinical trial updates, and more 👉 https://lnkd.in/egPa8gEq #asco2024 #breastcancer #oncology #cancersupport #digitalhealthstartup

🌟 Exciting 5-Year Results for ALK-Positive NSCLC Treatment! 🌟 The phase III CROWN study reports outstanding long-term outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC). Lorlatinib continues to shine with a median progression-free survival (PFS) still not reached after 5 years, marking the longest PFS ever recorded for single-agent targeted therapy! Plus, no new safety concerns have emerged. This is a significant milestone for NSCLC patients, showcasing the durability and efficacy of lorlatinib. #LungCancer #NSCLC #Oncology #CancerResearch #Lorlatinib #Crizotinib #CROWNStudy #ProgressionFreeSurvival #TargetedTherapy

Check out this drug reference sheet for lifileucel (Amtagvi™)!

First-Line Maintenance Strategies for Ovarian Cancer with Bevacizumab and PARP Inhibitors - EIOC - Excellence in Oncology Care https://lnkd.in/evXa5eC6 #Cancer #CME #MedicalEducation #DHA #DubaiHealthAuthority #OncoDaily #Oncology #OvarianCancer

Our oncology team is presenting new data in high-risk EGFR+ non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO).   At Johnson & Johnson Innovative Medicine, we believe that all patients deserve to receive advanced, personalized care early in the treatment journey—especially those patients who have disease with high-risk features. We are driving advancement in the front-line treatment of EGFR-mutated NSCLC with the goal of delivering the highest standard of care for patients. To read more about these data, view the press release here: https://bit.ly/4e9E9QQ     #MyCompany #LungCancer #Oncology #CancerResearch #NSCLC

📰by The Journal of Clinical Oncology, this international multicenter retrospective study of patients with RT who received CAR-T concluded that CAR-T demonstrates clinical efficacy for patients with RT. READ➡️https://lnkd.in/eN_8Civm #bloodcancer #hematology #oncology #cancer #leukemia #hematologyoncology

Approximately 36% of patients diagnosed with lung cancer receive the correct treatment. The AMCP Market Insights Best Practice webinar brings together Daryl Pritchard, Precision Medicine Coalition, and Susan Wescott, Mayo Clinic to discuss the key findings of the market insights roundtable on gaps that exist in the precision medicine side of non-small cell lung cancer (NSLC). View the NSLC Best Practice webcast today: https://bit.ly/4efCk4W #oncology #lungcancer #managedcare #pharmacy

For oncology patients navigating the particulars of their cancer and treatment plan, adding a clinical trial to the mix might feel overwhelming. To ensure a clinical trial for #oncology patients is successful, it must not impose additional burdens. The trial should address the needs of both the patients and their caregivers. Click the link to read more about the importance of #patientcentric oncology trials - https://lnkd.in/ek-FhRxx

Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with Resectable, Early-Stage NSCLC https://lnkd.in/eGzZdcFS 📢 @myESMO #MedicalOncology #CancerNews #Oncology #Cancer